Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
Xu YC, Johnson KW, Phebus LA, Cohen M, Nelson DL, Schenck K, Walker CD, Fritz JE, Kaldor SW, LeTourneau ME, Murff RE, Zgombick JM, Calligaro DO, Audia JE, Schaus JM. Xu YC, et al. Among authors: calligaro do. J Med Chem. 2001 Nov 22;44(24):4031-4. doi: 10.1021/jm0155190. J Med Chem. 2001. PMID: 11708905
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
Krushinski JH Jr, Schaus JM, Thompson DC, Calligaro DO, Nelson DL, Luecke SH, Wainscott DB, Wong DT. Krushinski JH Jr, et al. Among authors: calligaro do. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4. doi: 10.1016/j.bmcl.2007.07.086. Epub 2007 Aug 22. Bioorg Med Chem Lett. 2007. PMID: 17804228
Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.
Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer AD Jr, Branchek TA, Flaugh ME. Phebus LA, et al. Among authors: calligaro do. Life Sci. 1997;61(21):2117-26. doi: 10.1016/s0024-3205(97)00885-0. Life Sci. 1997. PMID: 9395253
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, Ho KH, Jarvie K, Rizkalla G, Wright RA, Calligaro DO, Schoepp D, Mattiuz EL, Stratford RE, Johnson B, Salhoff C, Katofiasc M, Phebus LA, Schenck K, Cohen M, Filla SA, Ornstein PL, Johnson KW, Bleakman D. Weiss B, et al. Among authors: calligaro do. J Pharmacol Exp Ther. 2006 Aug;318(2):772-81. doi: 10.1124/jpet.106.101428. Epub 2006 May 11. J Pharmacol Exp Ther. 2006. PMID: 16690725
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL. Rasmussen K, et al. Among authors: calligaro do. J Pharmacol Exp Ther. 2005 Dec;315(3):1265-77. doi: 10.1124/jpet.105.089326. Epub 2005 Sep 1. J Pharmacol Exp Ther. 2005. PMID: 16141369
The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.
Rasmussen K, Calligaro DO, Czachura JF, Dreshfield-Ahmad LJ, Evans DC, Hemrick-Luecke SK, Kallman MJ, Kendrick WT, Leander JD, Nelson DL, Overshiner CD, Wainscott DB, Wolff MC, Wong DT, Branchek TA, Zgombick JM, Xu YC. Rasmussen K, et al. Among authors: calligaro do. J Pharmacol Exp Ther. 2000 Aug;294(2):688-700. J Pharmacol Exp Ther. 2000. PMID: 10900249
66 results